Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioGenesis raises $6m for minimally invasive products:

This article was originally published in Clinica

Executive Summary

CardioGenesis, which makes surgical products and accessories for transmyocardial revascularisation (TMR) and percutaneous myocardial channelling (PMC) procedures, has raised $6m from Laurus Funds. It plans to use the proceeds to introduce new minimally invasive TMR products and fund further R&D. The company also wants to obtain FDA approval for its PMC technology. Chairman, president and CEO Michael Quinn said the minimally invasive tools should help expand the number of angina patients treated with TMR. To date about 30,000 patients have been treated.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060055

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel